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Lymphatic drainage function and its immunological implications:
From dendritic cell homing to vaccine design
Melody A. Swartz ∗, Jeffrey A. Hubbell, Sai T. Reddy
Institute of Bioengineering, ´Ecole Polytechnique Fe´de´rale de Lausanne (EPFL), Lausanne, Switzerland
bstract
The slow interstitial flow that drains fluid from the blood capillaries into the lymphatic capillaries provides transport of macromolecular nutrients
o cells in the interstitium. We discuss herein how this flow also provides continuous access to immune cells residing in the lymph nodes of antigens
rom self or from pathogens residing in the interstitium. We also address mechanisms by which dendritic cells in the periphery sense interstitial
ow to home efficiently into the lymphatics after activation, and how lymphatic endothelium can be activated by this flow, including how it can act
s a lymphatic morphoregulator. Further, we present concepts on how interstitial flow can be exploited with biomaterial systems to deliver antigen
nd adjuvant molecules directly into the lymphatics, to target dendritic cells residing in the lymph nodes rather than in the peripheral tissues,
sing particles that are small enough to be carried along by flow through the network structure of the interstitium. Finally, we present recent work
n lymphatic and lymphoid tissue engineering, including how interstitial flow can be used as a design principle. Thus, an understanding of the
hysiological processes that govern transport in the interstitium guides new understanding of both immune cell interactions with the lymphatics as
ell as therapeutic interventions exploiting the lymphatics as a target.
2007 Elsevier Ltd. All rights reserved.
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Dendritic cells (DCs) are the most potent and important
ntigen-presenting cells (APCs) because of their capacity to take
p and process antigens and present them to naı¨ve T cells [1,2].
hey also can fine-tune immune responses by instructing T cell
ifferentiation and polarization (i.e., they can induce humoral,
ellular (cytolytic), or suppressive responses in T cells). In addi-
ion to these important roles in biomolecular recognition and
ignaling, DCs are physically positioned to take up antigen from
eripheral tissues and carry them to the lymph node so that cir-
ulating T cells only need to traffic through the lymph nodes
o interact with all APCs. The lymphatic vessels are thus crit-
cal for transporting activated DCs from the periphery to the
ymph node. They constantly deliver a representative sampling
f interstitial fluid to the lymph node, allowing immature DCs
nd macrophages there to screen potential antigens and also to
arry inflammatory signals from the tissue (e.g., cytokines, extra-
ellular matrix fragments, etc.) to the lymph node faster than
eripheral, migrating DCs can, possibly preparing the lymph
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ode for the need to increase surveillance there in preparation for
pending immune response. Until recently, lymphatic vessels
ave been considered a passive conduit for immune cells. This
eview explores the links between lymphatic physiology and
iology with trafficking of antigen and DCs from the interstitium
f the peripheral tissues eventually into the lymph nodes, and
iscusses the implications of these links on immunomodulation
nd vaccination strategies.
. Interstitial ﬂow and lymphatic drainage
The lymphatic system complements the venous branch of
he circulation by draining excess fluid and solutes from the
nterstitial space and returning them to the blood. In this way,
ymphatic drainage facilitates low levels of interstitial flow from
he blood capillaries to perfuse the tissue interstitium; with-
ut this interstitial flow, transport of proteins, macromolecules,
iruses, nanoparticles, and other large solutes within the tis-
ue interstitium would occur by diffusion alone, which can be
xceedingly slow (diffusion coefficients on the order of 10−7
o 10−8 cm2/s for typical proteins). Importantly, lymphatics are
lso a major route for cell transport, since lymphatic capillar-
es drain to collecting vessels and pass through lymph nodes
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Fig. 1. Schematic of lymph flow. (A) Overall schematic showing lymphatic capillaries draining to collecting vessels and into lymph nodes. (B) Lymphatic capillaries
are arranged in an interconnected mesh-like network of vessels, as demonstrated here by the regular hexagonal network found in the mouse tail skin made visible by
the intradermal injection of a red fluorescent macromolecule (bar = 100m). (C) The major regions of the lymph node include the cortex, paracortex, and medulla, and
cortical nodules are divided by connective tissue called trabeculae. The cortex contains the primary cortical follicles that become secondary follicles with germinal
centers upon antigenic stimulation; the cortex is the primary site of B cell residence, antigen presentation, and antibody production. The paracortex surrounds the B
cell follicles and is the main site for T cell homing. DCs can be found throughout the node but are in highest numbers in the paracortex and medulla. Lymph enters
through afferent lymphatic vessels (that contain valves to prevent backflow), around the subcapsular sinus and into the node through a network of reticular fibers,
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ode stained for B cells (CD45R+ cells, green), T cells (CD3e+ cells, red), and
efore emptying into the blood via lymphatic ducts. Indeed,
ymph nodes (along with other secondary lymphoid organs such
s the spleen) are the most important sites for immune cells
o exchange information, reside, expand, and initiate adaptive
mmune responses. By draining interstitial fluid and carrying
ny potential antigens to lymph nodes, the lymphatic sys-
em optimizes immune response because it allows circulating
ntigen-specific lymphocytes to patrol all the lymph nodes for
heir cognate antigens rather than having to sample peripheral
issues directly. As such, one might also think of lymphatic ves-
els as “sensory” organs of the immune system, and of their
rainage function primarily as a means to sample peripheral
issue fluid and all antigens contained there (Fig. 1).
The lymphatic endothelium itself optimizes this transport
ole: it has discontinuous basement membrane and weak
ell–cell junctions, making it highly permeable to fluid and high
olecular weight solutes such as proteins and even nanoscale
olloidal particles. Lymphatic capillaries vary in size and are
ot circular in cross-section, and their diameters range from 10
o 80m [3–7]. They drain fluid by virtue of their anchoring
laments, which pull the lymphatic lumen open during slight
hanges in tissue hydration, causing a subsequent pressure drop
hat drives fluid flow into the lymphatic lumen [8]. Backflow
ut of the vessel is prevented by these overlapping cell–cell
t
a
t
tin in the subcapsular sinus and bypass the node. (D) Section of a mouse lymph
n-presenting cells (CD68+ macrophages and DCs, blue). Bar = 100m.
unctions that act like valves [3,4,9]: as the lymphatic capillary
lls, they close and prevent backflow. Thus, lymphatic function
auses interstitial fluid flow that is always directed towards the
raining lymphatic capillary.
Once lymph is formed into the lymphatic capillaries, it flows
o deeper collecting lymphatic vessels, which are segmented
nto lymphangions separated by valves and innervated by sur-
ounding smooth muscle cells that have intrinsic contractility
ith a magnitude range similar to that of cardiac muscle. Their
ehavior depends on pressure and flow conditions [10,11]: when
ransporting lymph up a pressure gradient, they contract and
ump fluid from one lymphangion to the next in a wave prop-
gation manner dependent on gap junctional communication
12], and when transporting lymph down a pressure gradient
high load conditions), they can act as conduits with decreased
ontraction amplitude, modulating tone and regulating flow
esistance. These prenodal collecting vessels are also referred
o as afferent lymphatic vessels and lead to lymph nodes, allow-
ng the contents of lymph to be sampled by immune cells as
ell as transporting activated dendritic cells there. In the human,here are 450 lymph nodes (22 in the mouse) and they are gener-
lly 1–2 cm in diameter (0.5–2 mm in mouse). Lymph can pass
hrough several different lymph nodes before being returned to
he blood via the thoracic duct.
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both DCs and LECs secrete CCL19, which competes with
CCL21 for CCR7 ligation but unlike CCL21 it does not bind
to sulfated proteoglycans in the matrix (and thus it exists only in
soluble form). The exact mechanism of this CCR7 ligand in mod-M.A. Swartz et al. / Seminars
. Flow through the lymph node
From the perspective of lymph flow, the lymph node archi-
ecture should be adapted in such a way that antigen-presenting
ells are exposed to any antigens or pathogenic material picked
p by the lymph from the peripheral tissues, and that immune
ell trafficking is optimized to allow the antigen-specific T cell to
nd its cognate antigen-presenting DC (Fig. 1C). Lymph flows
hrough the afferent vessels into the subcapsular sinus, through
apsular sinusoids and into the medullary sinusoids before leav-
ng the lymph node via efferent vessels. It can also flow through
ne reticular fibers that extend into the T cell regions [13,14]
nd where immature DCs, but not immigrated mature DCs,
ppear to also reside [15]. This reticular network consists of
ollagen fibers, basement membrane components, and retic-
lar fibroblastic cells [13], and is believed to further guide
ymph flow and T cell–DC interactions there [14]. Blood flows
hrough the high endothelial venules (HEVs) that have loose
ell–cell junctions and contain adhesion receptors like intercel-
ular adhesion molecule (ICAM)-1 and l-selectin to facilitate
xit of antigen-specific lymphocytes from the blood into the
ymph node in search of cognate antigen. Furthermore, activated
antigen-presenting) DCs migrate near these HEVs to optimize
heir chances of finding the rare antigen-specific naı¨ve T cell
artner. Cell migration and communication among immune cells
ithin the lymph node is complex and involves at least sev-
ral chemokine and sphingosine-1-phosphate (S1P) receptors
16] whose ligands are established by stromal cells as well as
mmune cells themselves [17–20]. Cell–cell communication and
robing is also enabled by the long dendritic extensions on DCs,
hich allow them to sample a much greater space, and there-
ore contact more T cells, than would be possible otherwise
21].
During inflammation, tissue fluid drainage can be increased
0-fold or more [6,22,23], which increases both the rate of anti-
en delivery from the periphery to the lymph node as well as
C trafficking (which will be explained below). Furthermore,
ytokines that are produced in the affected site are carried to
he draining lymph node, where they can induce changes in
he lymph node that enable and enhance immune cell traffick-
ng there, including the expansion of the feed arteriole which
ncreases blood flow and therefore lymphocyte trafficking to the
ffected node. For example, the inflammatory cytokines IL-6
nd IL-8 can increase the expression of lymphocyte receptors
ike ICAM-1 and the homing chemokine CCL21 by HEVs [24].
nflammation also apparently can induce expansion of the lym-
hatic network in the lymph node [1,25], which may help recruit
ore DCs from the periphery into the lymph node or enhance T
ell trafficking out of the node. Fever can also enhance ICAM-
, l-selectin, and CCL21 expression by HEVs. Thus, a number
f positive feedback mechanisms exist by which inflammation
nduces enhanced exposure of peripheral antigens to the lymph
odes.When lymphatic vessels are blocked or compromised in their
apacity to drain fluid, lymphedema can occur. This is asso-
iated with tissue fluid stagnation, enlargement of the limb,
ccumulation of lipids, and impaired immune function [26].
l
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ery little is known about how immune cell trafficking and the
mmune response is altered in lymphatic dysfunction, but, given
he importance of lymphatic drainage to antigen delivery to the
ymph node, and furthermore the importance of such interstitial
ow on the physiology of DC homing to the lymphatics (see next
ection), the limitations in the immune response must be sub-
tantial. Hopefully more research in this area will help elucidate
his topic in the near future.
. Implications of interstitial ﬂow on DC homing to
ymphatics
One implication of interstitial flow from the blood capillar-
es to the lymphatics may be the facilitation of DC homing
owards and into lymphatic capillaries, the first step in adaptive
mmunity, for example with Langerhans cells [2]. During these
nitial steps, DCs undergo a maturation process, which is medi-
ted by the inflammatory signals and characterized by altered
hemokine receptor expression including the downregulation of
CR1 and CCR5 (which bind CCL3 and RANTES) and the
pregulation of CCR4 (which facilitates DC–T cell interactions
n the lymph node) and, importantly, CCR7, which is neces-
ary for homing towards lymphatic capillaries [27–29] (Fig. 2).
heir transmigration into lymphatic vessels is not well under-
tood, as is their entry into the lymph node from the afferent
essels, although both are critical for the immune response. Both
nown CCR7 ligands, namely CCL21 (SLC or 6-C-kine) and
CL19 (ELC or MIP-3), appear to be important in DC hom-
ng [30–32]. It is generally assumed that DC trafficking towards
ymphatic vessels is primarily driven by chemotactic gradients
f lymphatic-secreted CCL21, and that lymphatic capillaries
roadcast this signal to attract DCs patrolling the interstitium.
However, this concept is confounded by two observations,
ndicating that there may be more subtle complexities to the
tory. First, the lymphatic capillary must broadcast CCL21
upstream”, i.e. against the draining flow into the capillary,
efore it can reach DCs in the interstitium. Given that the intersti-
ial flow is on the order of magnitude of 0.1–1.0m/s [33], this
epresents a potentially important factor in to overall CCL21
ransport. Second, CCL21 is strongly matrix-binding [34],
hich may substantially limit its broadcast distance through the
nterstitium; because of this, it is sometimes used as a marker for
ymphatic endothelium as it is mostly found on the basal surface
f lymphatic capillaries [35]. This situation is further exagger-
ted during acute inflammation, when interstitial drainage rates
an increase an order of magnitude or more [22,36–38], and
hen DC homing is greatest (i.e., when the CCL21 signal is
ost needed). Furthermore, it is also interesting to note that
11 We and others have noted that cultured LECs secrete CCL19 (unpub-
ished observations); lymphatic secretion of CCL19 in vivo has not been
ell-established.
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Fig. 2. The lymphatic microenvironment, and interstitial flow, in DC homing. (A) Inflammatory stimuli cause DCs to mature and, together with cytokines that
inflammatory cells recruited to the area can secrete, like TNF-, may also activate lymphatic endothelium to express receptors like ICAM-1 and l-selectin that may
aid in DC transmigration. The maturation process also induces DCs to upregulate CCR7, which binds CCL21 (or SLC) from lymphatic endothelium and thus induces
chemotaxis towards the lymphatic. DCs also produce the CCR7 ligand CCL19 (or ELC), which may attract other DCs to the site. (B) An important component of
the inflammatory environment that is usually not considered is increased interstitial flow and lymphatic drainage, which is brought about by increased filtration from
blood capillaries (due to hyperpermeability) as well as increased matrix proteolysis by inflammatory cells. This flow may limit the broadcast distance of CCL21
f r, this
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crom the lymphatic vessel (since it must diffuse against a convection). Moreove
radients—in this way, CCL19 secretion by DCs could act as a flow sensor and
ctivate lymphatic endothelial cells to change permeability or increase chemok
lating DC chemotaxis in the presence of CCL21 is unknown,
lthough when CCL19 is blocked, DC migration to lymph nodes
s reduced [32].
Furthermore, until very recently, the initial lymphatic ves-
el was considered a mostly passive conduit for DC trafficking
39], but new evidence suggests that the lymphatic vessels likely
lay a very active role. For example, it was recently shown
hat lymphatic endothelial adhesion receptor profiles change
fter exposure to inflammatory cytokines [40], although it is
ot known whether different molecules govern DC transmigra-
ion into lymphatics as opposed to leukocyte transmigration out
f blood capillaries. Also, lymphatic endothelial cells have been
hown to express Toll-like receptor (TLR) 2 and 4 [41], indicat-
ng that lymphatics may sense and respond to “danger signals”
n the periphery, perhaps to prepare themselves for eventual
C trafficking. Finally, it is likely that the physical microen-
ironment of lymphatics, namely slow interstitial flow through
3D matrix, can upregulate chemokine secretion and adhe-
ion molecule expression on lymphatic endothelium (Miteva
nd Swartz, unpublished observations), suggesting a role of
nterstitial flow in further guiding DCs to lymphatics.
. Exploiting interstitial ﬂow to target antigen to lymph
ode vs. peripheral DCs
For many years the conventional view was that immature
Cs existed only in peripheral tissues and that DCs in sec-
ndary lymphoid organs were in a mature state, i.e., they could
ot take up and process new antigen there. Therefore, vaccine
trategies have targeted peripheral DCs by delivering antigen
and adjuvant, as discussed further below) to peripheral DCs in
he skin or muscle, which in turn migrate to and enter the lym-
hatic capillaries and subsequently migrate to the lymph nodes
d
e
r
adraining flow can skew CCL19 distribution from the DC to create transcellular
t the DC towards the nearest draining lymphatic vessel. Finally, flow itself may
cretion, for example. These roles need to be further elucidated.
o present antigen and co-stimulatory molecules to T cells. How-
ver, recent work has demonstrated that such a generalized view
f DC phenotypes is inaccurate. A comprehensive study by Wil-
on et al. demonstrated indeed that the majority of DCs in lymph
odes (and spleen) were phenotypically and functionally imma-
ure [42]. These immature DCs in lymph nodes were found to
e constantly sampling self-antigen and presenting to T cells
or the purpose of maintaining tolerance; however when lymph
ode DCs were exposed to antigen simultaneously with a matu-
ation stimulus, they were able to activate T cells, suggesting that
hey are fully capable of triggering immune recognition while
esident within the lymph node and taking up antigen within the
ymph node. The high concentration of immature DCs in lymph
odes compared to that in the peripheral tissues and their abil-
ty to process and present antigen makes lymph node-resident
Cs an intriguing target for vaccine delivery, if co-delivery of
ntigen and adjuvant to the lymph node were achieved. As an
dditional benefit, there would be little risk of premature anti-
en presentation (when peripheral DCs become mature before
eaching the lymph node), which could lead to tolerance rather
han induction of adaptive immunity.
Exposure of DCs to antigen and activating molecules ex vivo
as been explored to increase targeting efficiency by avoid-
ng physiological barriers. Such ex vivo approaches have made
onsiderable progress in research as well as clinical develop-
ent; in such approaches, the DC is brought into direct contact
ith antigen and adjuvant ex vivo, obviating the need for any
iomolecular or physiological targeting strategy. Such strategies
onsist of isolating monocyte precursors from patient blood,
ifferentiating them into DCs with growth factor cocktails,
xposing them to antigen and maturation stimuli, and finally
e-injecting them back into patients [43–45]. One example of
n ex vivo autologous DC vaccine is the therapeutic vaccine
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PC8015 (Provenge; Dendreon Corp, WA) to treat metastatic
rostate cancer. In this strategy, isolated DCs are exposed to
recombinant fusion protein of GM-CSF attached to prostate
pecific antigen and then the DCs are injected into patients; a
hase III trial has shown prolonged survival in patients [46]. A
imilar strategy, where autologous DCs are pulsed with tumor
ell lysate from surgically resected brain cancer tissue (DCVax-
rain, Northwest Biopharmaceuticals, WA) has also reached
ate-stage clinical trials [47]. Despite the promise of ex vivo
C vaccines, many logistical and economical complexities and
herapeutic limitations remain. For example, autologous DC
accines are not a realistic option for prophylactic regimes or
reatment of infectious diseases in developing regions, where
here is the greatest need for new vaccines. Therefore a strong
nterest exists to develop more robust vaccines with in vivo DC
argeting.
Of course, targeting immature DCs residing in peripheral tis-
ue such as skin are the most widely explored vaccine targeting
pproaches. Non-specific uptake of particles by DCs has been
emonstrated with polymeric microparticles, virus-like parti-
les, and polystyrene nanobeads [45,48–51]. However, the low
oncentration of DCs in peripheral skin has motivated strate-
ies for more specific targeting through molecular recognition.
teinman and co-workers have designed a system to graft protein
ntigen to an antibody for the DC surface endocytosis receptor
EC205; they have demonstrated, with the addition of a molec-
lar danger signal adjuvant, the ability to induce potent adaptive
mmune responses following peripheral administration [52–54].
particulate approach has also been utilized for DC targeting
y conjugating anti-DEC205 and anti-CD11c to microparticles
nd liposomes, respectively [55,56]. While molecular targeting
f DCs has shown potential, there are still limitations in physi-
logical transport (mentioned below), and economic feasibility
hat must be considered as well.
As an alternative to the ex vivo manipulation and biomolec-
lar approaches mentioned above, we point out the basis for a
iophysical approach, namely that the interstitial flow that drains
uid from the blood capillaries into the lymphatic capillaries can
e exploited to deliver antigen to the lymphatics and thus to the
ymph node-resident DCs. A major challenge to exploiting this
ow is presented by the resistance to transport due to the net-
ork structure of the interstitium [57,58]. The interstitial space
ossesses a complex microarchitecture comprising fibrillar pro-
eins and proteoglycans and offers a high resistance to molecular
ransport through the interstitium. Several investigators have
emonstrated that the size of molecular solutes and nanoparti-
les influences their transport properties through the interstitium.
ne study quantified convective interstitial transport of injected
acromolecules and colloidal nanoparticles through the intersti-
ium in mouse skin and showed that solutes of 7–12 nm diameter
oved optimally through the interstitium and into the lymphat-
cs [59], and for nanoparticles, smaller was always better with
0–25 nm particles being taken up into the lymphatics from the
nterstitial space much more readily than 100 nm particles [60].
iposome transport in the interstitium and subsequent uptake
y the lymphatic capillaries and delivery to the lymph node has
lso been demonstrated to strongly depend on size, with 70 nm
a
n
d
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ppearing as a cutoff for interstitial liposomal transport [61].
t is noteworthy that the size cutoff for transport through the
nterstitium seems to be more stringent than size cutoff for entry
nto lymphatic capillaries through their valve structure, with the
nterstitial resistance offering the major barrier [62]. Thus, it is
pparent that interstitial flow may be used to direct nanoparti-
les to the lymph nodes, were DCs reside in high numbers, so
ong as the nanoparticles are sufficiently small to readily move
hrough the tissue interstitium.
From the perspective of lymph node targeting, it is unclear if
maller is always better—while smaller particles may enter lym-
hatics more effectively, they also tend to be cleared through the
ymph node more rapidly, partly because lymph node-resident
acrophages and DCs can take up larger particles more effi-
iently than smaller ones [63]. It is not known if this same
bservation would be true with particles bearing ligands for
acrophage and DC endocytosis receptors. Thus, from the per-
pective of efficient interstitial transport and prolonged lymph
ode retention, a delicate balance may exist and may require
ptimization for antigen delivery and retention to the lymph
odes via interstitial flow. The extent of this balance requires fur-
her elucidation, also in view of the unknown merits of prolonged
etention within the first lymph node draining the injection site
s. within several nodes along the lymphatic chain.
. Exploiting interstitial ﬂow to simplify adjuvant and
accine design
Because of the complexities of using attenuated pathogens,
long with recent advances in recombinant DNA technology,
accine technology approaches have shifted towards subunit and
enetic vaccines that use protein, peptide, and DNA-encoded
ntigen. To date, challenges exist in these types of antigens being
enerally weak immunogens, and therefore considerable atten-
ion is devoted to developing new molecular adjuvants, broadly
efined as compounds that enhance the immunogenicity of anti-
ens.
Most adjuvants have been developed to function in the periph-
ry. For example, the most widely used adjuvants are based on
luminum salts (alum). Despite nearly 60 years of clinical use,
complete mechanistic description of alum’s mode of action
emains elusive. Alum is thought to work by producing a depot
ffect and precipitating antigen so that it can be taken up more
ffectively by peripheral DCs [64]. In addition, alum induces
on-specific inflammation, which helps recruit more DCs to
he site of the injection depot. While alum is safe, it is also
onsidered relatively weak and only capable of inducing Th2
mmunity [65]. Therefore, a great deal of research exists to
evelop advanced adjuvants that are capable of inducing Th1
ell-mediated immune responses, which could provide better
rotection against viral and intracellular pathogens.
While alum was largely discovered through empirical meth-
ds, the recent explosion of knowledge in innate immunity has
llowed new adjuvant research to be driven by more ratio-
al approaches. By far the most research has focused on
esigning molecular danger signal adjuvants targeting TLRs
66]. Pattern recognition receptors like TLRs are activated by
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pathogen associated molecular patterns” (PAMPs). They are
resent on the surface and within the endosomes of many
ifferent immune cells, most notably DCs and macrophages.
he primary outcome of TLR activation on DCs is matura-
ion (upregulation of co-stimulatory molecules) and secretion
f inflammatory cytokines which often leads to strong Th1
esponses; therefore TLRs are excellent targets for vaccine
djuvants [67]. There have been at least 11 mammalian TLRs
iscovered to be activated by pathogenic signals such as bac-
erial lipopolysaccharide (LPS), fungal zymosan, viral single-
nd double-stranded RNA, and CpG containing DNA [68]. Syn-
hetic derivatives of TLR activators are currently being exploited
n experimental vaccine formulations. Monophosphoryl lipid
, a chemically modified derivative of LPS, signals through
LR4 and has seen significant clinical success in several vac-
ine formulations, including a vaccine for hepatitis B [66,69].
ther synthetic TLR agonists include unmethylated CpG DNA,
hich mimics a bacterial and viral DNA sequence that acti-
ates TLR9 [70]; polyinosinic:polycyidylic acid (poly I:C), a
ynthetic double-stranded RNA that activates TLR3 [71]; syn-
hetic lipopeptide tripalmitoyl-S-glyceryl cystein (Pam3Cys),
hich activates TLR2; and imidazoquinolines, which are small
olecule activators of TLR7/8 [70]. These TLR agonists are
eing explored in several experimental vaccines. In most if
ot all cases, they induce substantial expression and release of
nflammatory cytokines (which in turn recruit DCs to the injec-
ion site and contribute to their maturation); as such, there is a
elicate balance between efficacy and toxicity to be considered.
Co-administration of the antigen and adjuvant in a single
ano- or microparticle, which may also provide prolonged pres-
nce of the adjuvant, is a promising approach. Monophosphoryl
ipid A can be administered in soluble form or even precipitated
ith alum [72], but as elucidated above this makes it only able
o target peripheral DCs, being excluded from the lymphatics
y size. Co-loading of antigen and adjuvants into microparticles
nd liposomes has also been investigated, however the size of
hese carriers limits targeting to peripheral DCs at the site of
njection. In a study by Wang et al., microspheres composed
f poly(ortho ester) were designed to carry antigen-encoding
NA, protecting it from degradation and facilitating uptake into
ntigen-presenting cells [51]. Similar cancer vaccines based on
ene delivery with microspheres made of poly(-amino ester)
ave also been demonstrated in vivo [49,73]. Another micropar-
icle approach has explored targeting DCs with anti-CD11c
ntibody, grafted to acid-degradable microparticles carrying
rotein antigen [55] and achieved strong cellular immunity
hen co-loaded with CpG oligonucleotides as a TLR9 activa-
or [74]. Liposomes conjugated with DC-specific antibodies and
o-loaded with antigen and molecular danger signals have also
hown promising anti-tumor immunity [56].
Another major component of innate immunity is the com-
lement system, a pathway of biochemical defense consisting
f a number of proteins and enzymes that converge to opsonize
athogens and induce local inflammatory responses. Usually
onsidered the first line of defense, complement activation
as considered an effector arm of humoral (antibody) immu-
ity; however, recent work has demonstrated the importance of
c
a
t
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omplement in promoting adaptive immune responses as well.
djuvants utilizing the complement system have been explored;
ne strategy developed a fusion of C3b or C3d to model anti-
ens; following immunization in mice, a significant increase in
he acquired immune B cell response was observed compared to
ree antigen alone [75]. The mechanism has been explained by
he fact that C3b and C3d adjuvants work through direct binding
f the C3d receptor (CD21/35), which associates with CD19, a
nown amplifier of B cell activation [76]. Complement has also
een discovered to play a role in T cell-dependent immunity [77],
nd while a complete description of the molecular mechanisms
esponsible have yet to be described, it is likely that complement
roteins affect the complex signaling interactions between DCs
nd T cells [78].
This newly discovered role of complement in T cell immu-
ity suggests complement activation as a vaccine adjuvant. One
pproach to activating complement is with biomaterials, since it
s well-known that many polymer surfaces can activate com-
lement via the alternative pathway by reaction of hydroxyl
roups on the biomaterial surface reacting with C3, leading
o biomaterial-bound C3b [79,80]. For example, biomaterial
oatings with polyethylene glycol or its copolymers such as
luronic, used in many particle based delivery systems, have
een shown to activate complement [81,82]. The advances in
olecular understanding of innate immunity seen in recent years
ith TLRs and complement have brought incredible interest to
accine adjuvant research, as finally there is hope for a clinical
lternative to alum.
Returning to interstitial flow, and how recognition of its func-
ion would enable re-consideration and perhaps simplification
f adjuvant design, we have noted above the potential disadvan-
ages of coupling the adjuvant to particles so large as to exclude
ransport through the interstitium. We also noted that, if the anti-
en and adjuvant are both sufficiently small to be convected into
he lymphatics, there is no remaining need for an adjuvant to be
esigned to induce inflammation and thereby induce DC traffick-
ng to the peripheral site. Thus, agents that induce a less potent
esponse of cytokine expression and release may be considered,
nd, as such, a major source of toxicity might be avoided: it is
ot necessary for the adjuvant to induce inflammation to attract
nd recruit DCs to the site of injection, it need only activate the
Cs once it encounters them in the node.
As one specific approach to integrate the above knowledge of
C activation and interstitial transport into the lymphatics, very
mall polymer particles bearing both antigen and complement-
ctivating surface chemical features have been explored [60,83].
sing this approach, in situ complement activation served as
he danger signal for DC maturation. Further, this activation and
nduction of antigen presentation by the DCs occurred within the
ymph node, since the 20–25 nm nanoparticles employed were
onvected to the lymphatics within a few tens of minutes. Given
he high concentration of DCs present within the lymph node,
nd due to the efficient transport of the very small nanoparti-
les into the lymphatics, it was possible to deliver the antigen
nd adjuvant (on the same nanoparticles) to more than 50% of
he DCs present within the lymph node that drained the injection
ite—a remarkable level of efficient delivery. This approach was
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emonstrated to induce a strong humoral and cellular adaptive
mmune responses to antigen bound on the polymer nanopar-
icles, comparable to that achieved with LPS as the adjuvant,
hich is far too toxic to contemplate for clinical use. In spite of
his strong immune stimulation, signs of local inflammation that
ould be of clinical consequence were absent [83].
. Lymphatic tissue engineering
There is a need for lymphatic tissue engineering to gener-
te mimetics of the lymph node for basic biological studies, to
orm lymph node equivalents for immunotherapy, and to gen-
rate lymphatic vessels for basic physiological studies as well
s potentially for the treatment of lymphedema. Furthermore,
ymphatic vessel tissue engineering in biopolymer matrices, syn-
hetic matrices, or engineered tissues such as liver should be
central consideration in tissue engineering and regenerative
edicine, since lymphatic vessels are critically important for
oth modulating proper immune surveillance of the implanted
atrix or engineered tissue as well as maintaining hydrostatic
nd osmotic pressures there. At present, lymphatic tissue engi-
eering is very much in its infancy, and much of the above
emains conceptual, with only few foundational demonstrations
f those concepts.
Initial progress in lymph node tissue engineering has explored
eveloping model systems for studying the dynamic interactions
etween cells in the lymph node. Surface patterning meth-
ds have been employed to generate precise domains that bear
olecular signals that are normally presented by APCs, such as
cell receptor ligands and ICAM-1, to more precisely under-
tand the interactions between DCs as presenters of those signals
nd T cells as receivers and explore the regulation of synapse
ormation between them [84,85]; this is addressed elsewhere in
his issue. With regard to generation of engineered lymph node
nvironments for basic immunological investigation, porous
aterials have been explored as model microenvironments to
xplore the mechanisms by which DCs present ligands to a large
umber of T cells within the lymph node microenvironments
86].
Progress has also been made in formation of ectopic artificial
ymph node-like tissues for immunotherapy using biomateri-
ls and transplanted cells. Absorbable collagen sponges have
een seeded with thymus-derived stromal cells that expressed
ymphotoxin  receptors and vascular cell adhesion molecule
VCAM)-1 with and without co-seeding with activated bone
arrow-derived DCs. These constructs, when implanted in the
enal subcapsular space, evolved over a 3-week period of time
n vivo into lymph node-like tissues, displaying B cell and T cell
ones, germinal centers, follicular DC networks and even high
ndothelial venules, indicative of appropriate connection of the
rtificial lymph node to at least the blood vasculature [87]. These
rtificial lymph nodes have been demonstrated to be competent
o induce secondary immune responses in mouse models [88].
nitial results in generation of artificial lymph nodes are very
xciting, however even more exciting would be implantation
f cytokine-loaded biomaterial scaffolds to induce immigra-
ion of the appropriate immune, stromal and vascular cells to
l
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chieve lymph node-like structures, but this at present remains
n unrealized concept.
Lymphatic vessel tissue engineering, again very important
ut largely underdeveloped for the general field of tissue engi-
eering and regenerative medicine, can be considered in two
eneral approaches: (1) developing lymphatic capillary net-
orks in vitro (incorporated within the engineered tissue or
hroughout a synthetic or natural biopolymer matrix) that will
ater anastomose with existing lymphatics post-implantation,
nd (2) developing strategies to promote lymphangiogenesis
nto the implanted tissue or matrix-binding growth factors, or
ontrolled release of growth factors from implanted matrices.
Both approaches are newly facilitated by the recent explo-
ion of research in lymphangiogenesis biology, although much
till needs to be learned about the functional (as opposed to
evelopmental) biology of lymphatic endothelium. VEGF-C
nd VEGF-D, ligands of VEGFR-3, are the most well-studied
ymphatic growth factors, and play similar roles for lymphangio-
enesis to those of VEGF in blood angiogenesis; Prox-1 (which
romotes differentiation of the lymphatic lineage from veins),
ng-2 (which is important in lymphatic patterning), VEGF, and
any other factors have also been demonstrated to be critical for
ymphangiogenesis (reviewed in [89,90]). Aside from growth
actors, interstitial fluid flow has also been shown to play an
mportant organizational role in lymphangiogenesis both in vivo
35,91,92] and in vitro [93,94].
In vitro, lymphatic capillary networks have been created in
ollagen [93], fibrin [94], and collagen-fibrin mixtures [95],
sing slow interstitial flow as a guiding principle for exten-
ive formation of interconnected tubes with open lumen. In all
ases, a growth factor like VEGF or VEGF-C or a stimulant
ike PMA is also necessary for initiating lymphatic growth, via
roliferation and migration [96], and this has been achieved
or example using an engineered version of VEGF121 with
transglutaminase tag that covalently binds it into a fibrin
atrix upon crosslinking with Factor XIII [94,97], as well as
similar variant of VEGF-C (unpublished). VEGF165 naturally
inds to sulfated proteoglycans in the extracellular matrix, and
t is believed that this facilitates gradient formation to guide
ngiogenic sprouts through cell-released proteolysis; however,
t has also been suggested that the matrix-binding properties of
EGF allows interstitial flow to act as an organizational cue
ecause flow skews cell-released proteases in the flow direc-
ion and therefore matrix-liberated VEGF becomes biased, with
n amplified gradient, in the flow direction [94,98]. Thus, both
rowth cues (growth factors) and biophysical cues (interstitial
ow) are required for functional lymphatic capillary morpho-
enesis in vitro.
In vivo, VEGF-C delivery is being investigated as a potential
herapy for lymphedema and in wound healing. For example,
ollowing again the idea of heparin-binding growth factors in
ature, a VEGF-C/VEGF heparin-binding domain fusion pro-
ein was engineered and expressed in vivo via adenovirus,
eading to more efficient lymphangiogenesis than the WT-
EGF-C delivered the same way [99]. In vivo models of
ymphedema [100,101] have been used to show promise in
he potential of VEGF-C therapy [102]; however, it is not
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nown whether improvements in experimental lymphedema in
uch models are due to lymphangiogenesis, improved lymphatic
rainage due to VEGF-C effects on lymphatic function such as
ownstream lymphatic pump function [103], or other effects.
t is important to note that simply upregulating VEGF-C in a
issue with normal lymphatic vasculature can drive lymphatic
yperplasia and dysfunction [104], and thus more research,
imed at delivering VEGF-C in more physiologically relevant
ays (spatially and temporally controlled and co-delivery with
ther important growth factors) and at evaluating and optimiz-
ng function as well as morphology, is needed before therapeutic
ymphangiogenesis becomes a clinical reality.
. Conclusions
Expanding knowledge of lymphatic function and immune
ell trafficking into lymphatic vessels has allowed new insights
nto the mechanisms by which antigens from the peripheral
issues are efficiently delivered to DCs residing in the lymph
odes and likewise by which DCs from the periphery home
here. Moreover, this understanding has guided new strategies
n vaccine delivery, designing biomaterial delivery systems with
hysical characteristics that enable facile transport through the
issue interstitium under the influence of this interstitial flow
o target immature DCs that reside in the lymph nodes. More-
ver, such biomaterials systems can serve as powerful tools to
ore precisely study specific responses of, and complex inter-
ctions between, immune cells (this is the subject of another
hapter in this issue). For example, dendritic cell maturation
ollowing exposure to polymer films and particles has been
haracterized [105,106]; materials systems have been designed
o explore the connections of innate and adaptive immunity
n DC activation [83]; surfaces have been designed to quan-
itatively and controllably mimic DC-T cell interactions [84];
nd biomaterial microparticles have been loaded with chemoat-
ractants to investigate the effects of spatial gradients on cell
igration [107]. These and other advances, including continued
evelopment of engineered lymph node mimics and lymphatic
essels, designed in view of the physiology and biology of the
mmune system in mind, will be useful both as experimental
ools to probe biological mechanisms and as therapeutic tools in
mmunomodulation.
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